See more : Television Broadcasts Limited (TVBCY) Income Statement Analysis – Financial Results
Complete financial analysis of Edoc Acquisition Corp. (ADOC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Edoc Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Dongil Industries Co.,Ltd. (004890.KS) Income Statement Analysis – Financial Results
- G.F.C Green Fields Capital Ltd. (GFC-M.TA) Income Statement Analysis – Financial Results
- Transindia Real Estate Limited (TREL.BO) Income Statement Analysis – Financial Results
- Industrias Bachoco, S.A.B. de C.V. (IDBHF) Income Statement Analysis – Financial Results
- Ram Ratna Wires Limited (RAMRAT.NS) Income Statement Analysis – Financial Results
Edoc Acquisition Corp. (ADOC)
About Edoc Acquisition Corp.
Edoc Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the health care and health care provider space in North America and the Asia-Pacific. The company was incorporated in 2020 and is based in Victor, New York.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.54M | 1.80M | 0.00 |
| Gross Profit | -2.54M | -1.80M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 1.80M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 2.54M | 1.80M | 89.34K |
| Other Expenses | 2.54M | -70.30K | -565.30K |
| Operating Expenses | 2.54M | 1.80M | -565.30K |
| Cost & Expenses | 2.54M | 1.80M | -565.30K |
| Interest Income | 314.16K | 20.87K | 8.68K |
| Interest Expense | 36.10K | 5.03K | 0.00 |
| Depreciation & Amortization | 2.54K | 1.80K | 268.02 |
| EBITDA | -5.14K | 898.22 | -1.43K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.54K | -1.80K | -268.02 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.14M | 898.22K | -1.43K |
| Income Before Tax | -7.69K | -899.88 | -1.70K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.14K | 898.22 | -1.43K |
| Net Income | -7.69K | -899.88 | -1.70K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 5.93M | 11.80M | 11.80M |
| Weighted Avg Shares Out (Dil) | 5.93M | 11.80M | 11.80M |
ADOCIA: Upcoming Investor Meetings
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 - ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today that it will attend...
ADOCIA publie ses résultats financiers du premier semestre 2022 et dresse un bilan de ses activités
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC) (Paris:ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et d’autres maladies métaboliques, publie ce jour...
ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announces today its financial results for...
Adocia Will Release Its 2022 Half-year Results on September 19th and Hold a Webinar on September 20th
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 - ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, will release its first-half 2022 results on...
Adocia publiera ses résultats semestriels 2022 le 19 septembre et tiendra un webinaire le 20 septembre
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et d’autres maladies métaboliques, publiera ses résultats du...
Number of Shares and Voting Rights of ADOCIA as of August 31st, 2022
LYON, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter ADOCIA SA, a French...
ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 août 2022
LYON, France--(BUSINESS WIRE)--Regulatory News: Conformément aux dispositions de l’article L.233-8 II du Code de Commerce et de l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers (« AMF »). ADOCIA SA, 115, avenue Lacassagne, 69003 Lyon (Euronext Paris :...
ADOCIA annonce une première preuve de concept préclinique sur AdoShell® Islets pour le traitement du diabète de type 1 par thérapie cellulaire
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et d’autres maladies métaboliques, annonce l’établissement d’une première...
ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes
LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announces the establishment of a first proof...
Number of Shares and Voting Rights of ADOCIA as of July 31st, 2022
LYON, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter ADOCIA SA (Paris:ADOC), a...
Source: https://incomestatements.info
Category: Stock Reports